Can selumetinib be reimbursed through medical insurance?

As China continues to improve its drug policy for the treatment of rare diseases, selumetinib, a targeted treatment drug for pediatric patients with neurofibromatosis type 1 (NF1) accompanied by plexiform neurofibromatosis (PN), has been included in the National Medical Insurance Drug List. This progress marks a big step for China's medical insurance system in protecting the rights and interests of patients with rare diseases, and has also reduced the long-term medical burden for many families.

According to the latest medical insurance policy, the medical insurance payment scope of selumetinib is NF1 pediatric patients 3 years old and above with symptomatic, inoperable PN. After entering the medical insurance, its common specifications include 10 mg × 60 capsules and 25 mg × 60 capsules, which are suitable for precise treatment plans based on body surface area (BSA) grading. Since NF1 itself is a rare genetic disease, clinical treatment options are limited. Patients often have tumors that compress nerves and organs or cause deformities, which seriously affects their quality of life. Therefore, the coverage of targeted drugs is of great significance.

At the level of medical insurance implementation, although selumetinib is included in the catalog, patients still need to meet the specific conditions for use listed by the Medical Insurance Bureau. It usually includes a diagnosis certificate, medical institution level restrictions (if issued by a second-level hospital or above), expert prescriptions, and necessary examination data. After meeting the reimbursement conditions, insured patients can enjoy corresponding drug cost reimbursement according to local medical insurance policies, but the specific proportion may vary by region.

It is worth noting that the inclusion of selumetinib in the medical insurance catalog was reached through negotiation, which shows that the state has made important coordination with drug manufacturers on price. Without affecting the quality and efficacy of the drug, the retail price of the drug on the market has been greatly reduced, saving patients a lot of economic costs.

Reference materials:https://www.koselugo.com